Member Info for Laura2022

...

2 shares at lows but with cash more than market cap (NANO cash £10mln v £5mln) SOU cash £8mln v £6mln

Under 2p

Need to click as not easy to copy format

https://www.nanocotechnologies.com/investors/reasons-to-invest/

Pioneer in cadmium-free quantum dot technology

Large and Defensible IP Portfolio

0

patents granted and pending

Market Opportunity for QD Materials

$ 0 bn

By 2030

Continuing investment in R&D

£ 0.0 m

invested in 2025

Significant manufacturing scale

2 bn

sensor capacity

Highly innovative employees

9

listed inventors

IP LICENCE PARTNER

This should be a very busy person

I'll certainly emailing her

7. Questions

Any questions should be submitted in advance of the Meeting by emailing such questions to the Company

Secretary at LGray@nanocotechnologies.com. Please include in your email: the shareholder’s full name,

number of shares held and telephone contact details.

Should you have any queries relating to shareholder voting, please contact Sodali & Co at

nanoco@info.sodali.com.

Thought this was interesting from final results

P140 - World's first immunormalizer

P140 (Lupuzor™, forigerimod) is a first-in-class peptide-based therapy designed to address the root cause of autoimmune and inflammatory diseases. Unlike current therapies that aim to suppress or modulate immune activity, P140 selectively restores immune balance without compromising healthy immune function. By directly targeting key pathways involved in immune tolerance, P140 represents a new therapeutic category: an immunormalizer.

 

The current standard of care in autoimmune disease primarily focuses on controlling inflammation rather than addressing its root cause. ImmuPharma is pioneering a new therapeutic paradigm through its proprietary platforms:

 

· Restoring immune tolerance instead of broad suppression

· Identifying and targeting the right patients through companion diagnostics

· Building a precision medicine ecosystem that enables durable remission and improved long-term outcomes

 

This differentiated strategy positions ImmuPharma at the intersection of immunology, precision medicine, and peptide-based therapeutics, areas driving the next wave of biomedical innovation.

 

A new therapeutic paradigm

 

Autoimmune diseases represent one of the fastest-growing therapeutic areas worldwide, affecting an estimated 3-10% of the global population. Despite this high burden, current treatment strategies remain largely focused on symptom management rather than addressing the root cause of disease.

This is highly unusual to only have the CEO recommending the deal ( see the GM circular on website ) and no otjer "irrevocable undertakings " support from ANY major holders

So far, albeit only 3 days, there have been no large delayed funds belonging out or TR1s

I think someone WILL buy it

The IP has to be worth £10mln-20mln +then the cash of £10mln + £1mln for market listing

Versus £5mln cap

Leafie

You decided at nearly midnight to commence a discussion point like that?

Not as meaningless as most of your posts on every company

Green box

Globex

Very detailed synopsis , thanks

Bently

Shhhh

Don't wake the troll :)

Balance

You'll never be able to reason with a fool , an angry abusive one at that

Sometimes we have to accept there are just some horrible people out there

Filtering is the solution

With a fresh pair of eyes and without the weight of timescales missed ( and missing the strange jeckll and Hyde posters ) it seems like 2026 will be THE year for P140

and , as an aside, those who dont should simply move on for their own peace of mind

Best wishes

Ill be voting NO with just over 1mlnn shares

Course they do

All companies will monitor social media

Its how trolls get caught out and can end in litigation

Professor

Good posts

I think someone WILL buy it

The IP has to be worth £10mln-20mln +then the cash of £10mln + £1mln for market listing

Versus £5mln cap

Moving

Nice buys

Jvip

Evening

Interesting one over at NANO

think IQE 5p to 50p

Someone is collecting as they'll take 650,000 at2.7p